Sipuleucel-T and Androgen Receptor-Directed Therapy for Castration-Resistant Prostate Cancer: A Meta-Analysis

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

Citation
Yi, Renliang, Baoxin Chen, Peng Duan, Chanjiao Zheng, Huanyu Shen, Qun Liu, Chen Yuan, Weilin Ou, and Zhiheng Zhou. 2016. “Sipuleucel-T and Androgen Receptor-Directed Therapy for Castration-Resistant Prostate Cancer: A Meta-Analysis.” Journal of Immunology Research 2016 (1): 4543861. doi:10.1155/2016/4543861. http://dx.doi.org/10.1155/2016/4543861.

Published Version
doi:10.1155/2016/4543861

Citable link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:30370928

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Review Article

Sipuleucel-T and Androgen Receptor-Directed Therapy for Castration-Resistant Prostate Cancer: A Meta-Analysis

Renliang Yi,1 Baoxin Chen,2 Peng Duan,2 Chanjiao Zheng,2 Huanyu Shen,2 Qun Liu,2 Chen Yuan,2 Weilin Ou,2 and Zhiheng Zhou3

1Guangzhou Hospital of Guangzhou Military Region, Guangzhou, China
2School of Public Health, Guangzhou Medical University, Guangzhou, China
3Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

Correspondence should be addressed to Zhiheng Zhou; zhihengz@163.com

Received 11 March 2016; Revised 28 August 2016; Accepted 18 September 2016

Copyright © 2016 Renliang Yi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

New treatments, such as sipuleucel-T and androgen receptor- (AR-) directed therapies (enzalutamide (Enz) and abiraterone acetate (AA)), have emerged and been approved for the management of castration-resistant prostate cancer (CRPC). There are still debates over their efficacy and clinical benefits. This meta-analysis aimed to investigate the efficacy and safety of sipuleucel-T and AR-directed therapies in patients with CRPC. RevMan 5.1 was used for pooled analysis and analysis of publication bias. Seven studies were included in the meta-analysis, with three studies in sipuleucel-T (totally 737 patients, 488 patients in treatment group, and 249 patients in placebo group) and four in AR-directed therapies (totally 5,199 patients, 3,015 patients in treatment group, and 2,184 patients in placebo group). Treatment with sipuleucel-T significantly improved overall survival in patients with CRPC and was not associated with increased risk of adverse event of grade \( \geq 3 \) (\( p > 0.05 \)). However, treatment with sipuleucel-T did not improve time-to-progression and reduction of prostate-specific antigen (PSA) level \( \geq 50\% \) was not significantly different from that with placebo. AR-directed therapies significantly improved overall survival in patients with CRPC and improved time-to-progression and reduction of PSA level \( \geq 50\% \). AR-directed therapies did not increase risk of adverse event of grade \( \geq 3 \) (\( p > 0.05 \)).

1. Introduction

Prostate cancer is one of the most frequently diagnosed cancers in men. Worldwide, in 2015, it is the second most common newly diagnosed cancer and the fourth most common cause of cancer death in men. In the United States, incidence and mortality of prostate cancer ranked first and second, respectively, in men. Over the past few years, incidence of prostate cancer increased steadily, with slowly increased mortality [1–3]. Current treatments for prostate cancer include surgical and medically induced castration and androgen deprivation therapy (ADT) using androgen receptor (AR) antagonists [4]. Despite these treatments, a sizable number of patients will eventually experience disease recurrence and progression [5]. Castrate-resistant prostate cancer (CRPC) is defined as disease progression despite ADT and may present a spectrum of disease ranging from rising prostate-specific antigen (PSA) levels, progression of preexisting disease, or appearance of new metastases [6–8]. CRPC poses a great challenge in the management of prostate cancer.

Docetaxel, approved by the US Food and Drug Administration (FDA) in 2004, is a taxane drug that induces polymerization of microtubules and phosphorylation of Bcl-2 protein. Three weeks of combined docetaxel and prednisone is currently considered the standard of first-line chemotherapy for men with CRPC [9]. The second-line chemotherapy with cabazitaxel has been shown to increased survival time in patients with CRPC. However, severe adverse events have been reported for these treatments [10, 11]. With advances in the understanding of disease pathophysiology, new treatments for CRPC emerge in the recent years that aim to improve both survival and quality-of-life of patients [12]. These treatments include cancer immunotherapy such as sipuleucel-T, AR-directed therapies such as abiraterone...
acetate (AA) and enzalutamide (Enz), radium-223, and PROSTVAC [13–18]. Radium-223 is mainly used to manage bone metastases in CRPC [19]. Trials of immunotherapy of PROSTVAC which utilizes recombiant poxviruses to express PSA are ongoing [20]. Phase III clinical trials have been conducted for sipuleucel-T, AA, and Enz and FDA has approved their use in patients with CRPC [21–23]. These new treatments hold great potential as the first-line treatments for patients with CRPC. Finding the optimal regimen is now the major clinical challenge. This meta-analysis aimed to investigate and compare the efficacy and safety of these two treatments and to provide scientific evidence for the management of CRPC.

AA is a steroidal antiandrogen that exerts its effect through inhibiting CYP17A and it also acts as an antagonist of AR [24, 25]. Clinical trials showed significantly improved survival for treatment with AA compared with placebo. It was approved by the FDA in 2011 for patients with CRPC. Enz is a synthetic nonsteroidal pure antiandrogen. It has a strong binding affinity for AR and in addition prevents binding of AR to deoxyribonucleic acid and AR to coactivator proteins [26]. It was approved by the FDA in 2012 for patients with CRPC.

Sipuleucel-T (PROVENGE®) is an autologous vaccine. The antigen presenting cells (APCs) are harvested from individual patient's peripheral blood and later incubated with recombiant fusion protein antigen, which contains both prostatic acid phosphatase and granulocyte-macrophage colony-stimulating factor [27, 28]. This process activates the APCs, which are critical for priming a cytotoxic T-lymphocyte-mediated immune response [27]. These activated APCs are then reinfused into the individual patient. In 2010, sipuleucel-T became the first immune-therapeutic agent approved by the FDA for patients with CRPC, based on consistent observed improvement in overall survival.

This meta-analysis aimed to further determine the clinical efficacy and safety of these two types of treatments, namely, sipuleucel-T and AR-directed therapies (AA and Enz), in the management of CRPC. Survival and disease progression were assessed by overall survival (OS) and time-to-progression (TTP) [29], respectively. Biological endpoint was assessed as a ≥50% reduction of PSA level. Adverse events of grade ≥3 were also reviewed.

2. Methods

2.1. Literature Search and Study Selection. We systematically searched seven literature databases (OVID, Springer, PubMed, Web of Science, ScienceDirect, Medline, and Cochrane Library) from 1966 to October 2015 for all relevant articles by entering terms including "castrate-resistant prostate cancer", "sipuleucel-T", "enzalutamide", and "abiraterone acetate" as key words, title, subject heading, and text word. We also searched for potentially missed articles from the reference list of retrieved articles and from previous narrative reviews on this topic.

Studies were included if they met the following criteria: (1) randomized double-blind place-controlled clinical trials of sipuleucel-T, AA, and Enz presenting original data; (2) patients with CRPC; (3) English articles published before October 2015. In case of duplicated reports, the article presenting the latest and the most comprehensive data on the largest cohorts was selected. Studies were excluded if (1) they were duplicated reports, were of poor quality, were lacking original data, or presented incomplete data; (2) they were review articles, conference abstracts, or commentary. Two authors (Renliang Yi and Baoxin Chen) conducted literature search and study selection independently. Results were compared and discrepancies were resolved by a discussion with another author (Peng Duan).

2.2. Quality Assessment. Full text of articles that fulfilled inclusion and exclusion criteria were retrieved for review. Quality of the included articles was assessed using the Newcastle-Ottawa Scale (NOS) [30], in which a study is judged on three broad perspectives: the selection of the study groups (adequate definition of the cases, representativeness of the cases, selection of controls, and definition of controls), the comparability of the groups (compatibility of cases and controls), and the ascertainment of the outcome of interest (ascertainment of exposure, ascertainment of cases and controls, and nonresponse rate). Total score of NOS is nine, with higher score indicating higher quality. Two authors (Qun Liu and Chen Yuan) conducted quality assessment independently. Results were compared and discrepancies were resolved by a discussion with another author (Weilin Ou).

2.3. Data Extraction. The following outcomes were extracted from each study: OS, TTP, reduction of PSA level ≥50%, and adverse events of grade ≥3. Two authors (Chanjiao Zheng and Huanyu Shen) conducted data extraction independently. Results were compared and discrepancies were resolved by a discussion with corresponding author (Zhiheng Zhou).

2.4. Data Synthesis and Analysis. Review Manager 5.1 software was used for data synthesis and analysis. The hazard ratio (HR) with 95% confidence interval (CI) was calculated for dichotomized data. Quantitative data were expressed as weighted mean difference (WMD) with 95% CI. Heterogeneity analysis was performed using $q$ test with $p > 0.1$ and $I^2 < 50\%$ suggesting homogeneity among studies. For data without significant heterogeneity, fixed-effect models were used for pooled analyses. In case of significant heterogeneity, sensitivity analysis was performed by excluding the study with the highest variance. In the case that no definite cause was found for heterogeneity, random-effect model was used for pooled analyses. The significance of pooled data was further tested and a $p < 0.05$ was considered statistically significant. When enough studies were included, funnel plot was delineated and the publication bias was evaluated.

3. Results

3.1. Study Selection. Our search resulted in 571 articles. A total of 302 articles were excluded after reviewing titles and abstracts, and 80 articles were excluded due to duplicated reports. A total of 182 articles were further excluded after full-text review. Exclusion reasons included review articles...
Potentially relevant studies identified, \( n = 571 \)

Excluded based on
Title or abstract, \( n = 302 \)
Repeated studies, \( n = 80 \)

Excluded due to
Reviews, \( n = 51 \)
Letters or comments, \( n = 18 \)
Being not a randomized trial, \( n = 45 \)
Lack of data on important factor, \( n = 68 \)

Group sipuleucel-T full text viewed, \( n = 39 \)
Group abiraterone acetate full text viewed, \( n = 89 \)
Group enzalutamide full text viewed, \( n = 61 \)

Total studies included, \( N = 7 \)

Figure 1: Flow chart of study selection. The summary of the study selection process was shown by flow chart.

### Table 1: Quality indicators by Newcastle-Ottawa Scale.

| Studies | Selection | Comparability | Exposure | Score |
|---------|-----------|---------------|----------|-------|
| Beer and Tombal, 2014 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | 8 |
| Fizazi et al., 2012 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | 9 |
| Higano et al., 2009 | Yes | Yes | Yes | Yes | No | Yes | Yes | Yes | 8 |
| Kantoff et al., 2010 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | 9 |
| Rathkopf et al., 2014 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | 9 |
| Scher et al., 2012 | Yes | Yes | Yes | Yes | No | Yes | Yes | Yes | 8 |
| Small et al., 2006 | Yes | Yes | Yes | Yes | No | Yes | Yes | Yes | 8 |

(1): case independent validation; (2): representativeness of the cases; (3): community or hospital controls; (4): history of disease; (5A): study controls for the most important factor; (5B): study controls for any additional factor; (6): ascertainment of exposure; (7): was follow-up long enough for outcomes to occur? (8): adequacy of follow-up of cohorts.

3.2. Study Characteristics. All seven studies were randomized, double-blind, placebo-controlled clinical trials. Results of quality assessment using NOS for the seven studies are showed in Table 1. The seven studies included a total of 5,936 patients with CRPC. Table 2 shows the main characteristics of the included studies. Regimens used in these studies were as follows: (1) sipuleucel-T: patients were randomly assigned in a 2:1 ratio to receive either sipuleucel-T or placebo every two weeks, for a total of three infusions; (2) AA: intervention group received combined AA 1000 mg and prednisone 10 mg daily and placebo group received prednisone 10 mg daily plus placebo; (3) Enz: intervention group received Enz 60 mg daily and placebo group received placebo.

3.3. Overall Survival (OS). All seven studies provided data on survival with follow-up period up to 36 months [29, 31–36]. Analyses of OS were performed in 5,936 patients, with 737 patients for sipuleucel-T (intervention group versus placebo group: 488 versus 249 patients) and 5,199 patients for AR-directed therapies (intervention group versus placebo group: 3,015 versus 2,184 patients). Figure 2 shows the forest plot of analysis of OS. Results showed that, compared with placebo, both sipuleucel-T and AR-directed therapies significantly improved survival of patient with CRPC. Pooled HR for OS was 0.73 for sipuleucel-T (95% CI: 0.61–0.88; \( Z = 3.31; p < 0.001 \)) and 0.72 for AR-directed therapies (95% CI: 0.66–0.78; \( Z = 7.94; p < 0.00001 \)). Tests for heterogeneity showed insignificant results, indicating homogeneity among studies (both \( p > 0.1 \) and both \( I^2 < 50\% \)).

3.4. Time-to-Progression (TTP). Six studies with a total of 5,936 patients reported TTP [29, 31–35], including 737 patients for sipuleucel-T (intervention group versus placebo...
Test for heterogeneity was not significant (HR of 0.88 (95% CI: 0.74–1.06; showed no significant favorable effect on TTP with pooled analysis of TTP. Compared with placebo, sipuleucel-T 3,015 versus 2,184 patients). Figure 3 shows the forest plot directed therapies (intervention group versus placebo group: 488 versus 249 patients) and 5,199 patients for AR-directed therapies (intervention group versus placebo: 1,717 CRPC: castration-resistant prostate cancer; OS: overall survival; TTP: time-to-progression; PSA: prostate-specific antigen; AEs: adverse events.

The central vertical solid line indicates the HRs for null hypothesis. The size of the diamonds represents the weight for the random-effect model in the meta-analysis.

Figure 2: Forest plot of hazard ratio of overall survival of sipuleucel-T and androgen receptor-directed therapies compared with placebo in men with castration-resistant prostate cancer. The bars with squares in the middle represent 95% confidence intervals (95% CIs) and HRs. The size of the diamonds represents the weight for the random-effect model in the meta-analysis.

Table 2: Main characteristics of included studies.

| Study                  | N  | Patients | Design                                | Interventions                  | Primary endpoint |
|------------------------|----|----------|---------------------------------------|-------------------------------|------------------|
| Small et al., 2006     | 127| CRPC     | Randomized, double-blind, placebo-controlled| Sipuleucel-T, placebo          | OS, TTP, reduction of PSA > 50%, AEs grade ≥ 3 |
| Higano et al., 2009    | 98 | CRPC     | Randomized, double-blind, placebo-controlled| Sipuleucel-T, placebo          |                  |
| Kantoff et al., 2010   | 512| CRPC     | Randomized, double-blind, placebo-controlled| Sipuleucel-T, placebo          |                  |
| Fizazi et al., 2012    | 1195| CRPC   | Randomized, double-blind, placebo-controlled| Sipuleucel-T, placebo          |                  |
| Rathkopf et al., 2014  | 1088| CRPC    | Randomized, double-blind, placebo-controlled| Abiraterone acetate, placebo   |                  |
| Scher et al., 2012     | 1199| CRPC    | Randomized, double-blind, placebo-controlled| Enzalutamide, placebo          |                  |
| Beer and Tombal, 2014  | 1717| CRPC    | Randomized, double-blind, placebo-controlled| Enzalutamide, placebo          |                  |

CRPC: castration-resistant prostate cancer; OS: overall survival; TTP: time-to-progression; PSA: prostate-specific antigen; AEs: adverse events.

3.5. Reduction of PSA Level ≥50%. Seven studies with a total of 5,936 patients reported reduction of PSA level ≥50% as study outcome [29, 31–36], including 689 patients for sipuleucel-T (intervention group versus placebo group: 458 versus 231 patients) and 4,975 patients for AR-directed therapies (intervention group versus placebo group: 2,928 versus 2,047 patients). Pooled RR showed that sipuleucel-T has no significant effect on reducing PSA level ≥50% (RR: 2.51; 95% CI: 0.65–9.73; Z = 1.33; p = 0.18). Test for heterogeneity was not significant (p = 0.5; I² = 0%). In contrast, AR-direct therapies showed significant effect on reducing PSA level ≥50% (RR: 9.82; 95% CI: 1.99–48.46; Z = 2.89; p = 0.004) (Figure 4).

3.6. Adverse Events (Grade ≥3). To investigate the safety of these treatments, we compared the occurrence of adverse events of grade ≥3, including fatigue, headache, back pain, arthralgia, constipation, and diarrhea, with that in placebo. Pooled RR revealed that, compared with placebo, risk of adverse event was not significantly increased for sipuleucel-T and AR-directed therapies (p > 0.05, Table 3 and Figure 5). There were also no significant adverse events related to these two treatments.

Favors experiment Favors control

0.05 0.2 1 5 20

Total

3503 2433 100.0%
| Study or subgroup          | log[hazard ratio] | Experiment | Control | Weight | Hazard ratio | Hazard ratio |
|---------------------------|-------------------|------------|---------|--------|--------------|--------------|
|                           |                   | SE        | Total   |        | IV, random, 95% CI | IV, random, 95% CI |
|                           |                   |            |         |        |              |              |
| **2.2.1 Sipuleucel-T**    |                   |            |         |        |              |              |
| Higano et al. 2009        | -0.0834           | 0.2354     | 65      | 33     | 0.92 [0.58, 1.46] |              |
| Kantoff et al. 2010       | -0.0513           | 0.1072     | 341     | 171    | 0.95 [0.77, 1.17] |              |
| Small et al. 2006         | -0.3711           | 0.1959     | 82      | 45     | 0.69 [0.47, 1.01] |              |
| **Subtotal (95% CI)**     |                   | 488        | 249     | 45.2%  | 0.88 [0.74, 1.06] |              |
|                           |                   |            |         |        |              |              |
| Heterogeneity: $\chi^2 = 2.08$, df = 2 ($p = 0.35$); $I^2 = 4\%$ |
| Test for overall effect: $Z = 1.35$ ($p = 0.18$) |
|                           |                   |            |         |        |              |              |
| **2.2.2 Androgen receptor-directed therapies** | | | | | | |
| Fizazi et al. 2012        | -0.4155           | 0.0659     | 797     | 398    | 0.66 [0.58, 0.75] |              |
| Rathkopf et al. 2014      | -0.2357           | 0.0917     | 546     | 542    | 0.79 [0.66, 0.95] |              |
| Scher et al. 2012         | -0.9163           | 0.0681     | 800     | 399    | 0.40 [0.35, 0.46] |              |
| **Subtotal (95% CI)**     |                   | 2143       | 1339    | 54.8%  | 0.59 [0.40, 0.88] |              |
|                           |                   |            |         |        |              |              |
| Heterogeneity: $\chi^2 = 44.64$, df = 2 ($p < 0.00001$); $I^2 = 96\%$ |
| Test for overall effect: $Z = 2.59$ ($p = 0.009$) |
|                           |                   |            |         |        |              |              |
| **Total**                 |                   | 2631       | 1588    | 100.0% |              |              |

**Figure 3:** Forest plot of hazard ratio of time-to-progression of sipuleucel-T and androgen receptor-directed therapies compared with placebo in men with castration-resistant prostate cancer. The bars with squares in the middle represent 95% confidence intervals (95% CIs) and HRs. The central vertical solid line indicates the HRs for null hypothesis. The size of the diamonds represents the weight for the random-effect model in the meta-analysis.

| Study or subgroup          | Experiment | Control | Weight | Risk ratio | Risk ratio |
|---------------------------|------------|---------|--------|------------|------------|
|                           | Events     | Total   |        | M-H, random, 95% CI | M-H, random, 95% CI |
|                           |            |         |        |              |              |
| **3.3.1 Sipuleucel-T**    |            |         |        |              |              |
| Kantoff et al. 2010       | 8          | 311     | 2      | 153        | 1.97 [0.42, 9.15] |
| Small et al. 2006         | 5          | 147     | 0      | 78         | 5.87 [0.33, 104.82] |
| Higano et al. 2009        |            | 458     | 231    | 25.5%      | 2.51 [0.65, 9.73] |
| **Subtotal (95% CI)**     |            | 13      | 2      | 10.2%      |              |
| Total events              |            | 1670    | 210    | 74.5%      |              |
|                           |            |         |        |              |              |
| Heterogeneity: $\chi^2 = 0.45$, df = 1 ($p = 0.50$); $I^2 = 0\%$ |
| Test for overall effect: $Z = 1.33$ ($p = 0.18$) |
|                           |            |         |        |              |              |
| **3.3.2 Androgen receptor-directed therapies** | | | | | | |
| Beer and Tombal 2014      | 666        | 854     | 27     | 777        | 18.9%      | 22.44 [15.47, 32.57] |
| Fizazi et al. 2012        | 235        | 797     | 22     | 598        | 18.8%      | 5.33 [3.50, 8.12] |
| Rathkopf et al. 2014      | 374        | 546     | 156    | 542        | 19.1%      | 2.38 [2.06, 2.75] |
| Scher et al. 2012         | 395        | 731     | 5      | 330        | 17.7%      | 35.66 [14.91, 85.33] |
| **Subtotal (95% CI)**     |            | 2928    | 2047   | 74.5%      | 9.82 [1.99, 48.46] |
| Total events              |            | 1670    | 210    | 74.5%      |              |
|                           |            |         |        |              |              |
| Heterogeneity: $\chi^2 = 239.10$, df = 3 ($p < 0.00001$); $I^2 = 99\%$ |
| Test for overall effect: $Z = 2.80$ ($p = 0.005$) |
|                           |            |         |        |              |              |
| **Total**                 |            | 3386    | 2278   | 100.0%     |              |

**Figure 4:** Forest plot of risk ratio of reduction of prostate-specific antigen ≥50% of sipuleucel-T and androgen receptor-directed therapies compared with placebo in men with castration-resistant prostate cancer. The bars with squares in the middle represent 95% confidence intervals (95% CIs) and RRs. The central vertical solid line indicates the RRs for null hypothesis. The size of the diamonds represents the weight for the random-effect model in the meta-analysis.
| Study or subgroup | Experiment Events | Control Events | Total Events | Weight M-H, fixed, 95% CI | Risk ratio M-H, fixed, 95% CI |
|------------------|------------------|----------------|--------------|--------------------------|-----------------------------|
| **5.10.1 Fatigue: sipuleucel-T** | | | | | |
| Higano et al. 2009 | 1 | 65 | 0 | 33 | 12.4% | 1.55 [0.96, 2.66] |
| Kantoff et al. 2010 | 4 | 338 | 3 | 168 | 75.5% | 0.66 [0.51, 1.30] |
| Small et al. 2006 | 1 | 82 | 0 | 45 | 12.1% | 1.66 [0.49, 5.85] |
| **Subtotal (95% CI)** | 485 | 246 | 246 | 100.0% | 0.89 [0.27, 3.01] |
| **Total events** | 6 | 3 | 9 | | |
| Heterogeneity: $\chi^2 = 0.42, df = 2$ ($p = 0.81$); $I^2 = 0$% |
| Test for overall effect: $Z = 0.18$ ($p = 0.86$) |
| **5.10.2 Fatigue: androgen receptor-directed therapies** | | | | | |
| Beer and Tombal 2014 | 16 | 871 | 16 | 844 | 13.6% | 0.97 [0.49, 1.93] |
| Fizazi et al. 2012 | 72 | 791 | 41 | 394 | 45.7% | 0.87 [0.61, 1.26] |
| Rathkopf et al. 2014 | 13 | 542 | 10 | 540 | 8.4% | 1.30 [0.57, 2.93] |
| Scher et al. 2012 | 50 | 800 | 29 | 399 | 32.3% | 0.86 [0.55, 1.34] |
| **Subtotal (95% CI)** | 3004 | 2177 | 96 | 100.0% | 0.92 [0.72, 1.18] |
| **Total events** | 151 | 96 | 247 | | |
| Heterogeneity: $\chi^2 = 0.86, df = 3$ ($p = 0.84$); $I^2 = 0$% |
| Test for overall effect: $Z = 0.68$ ($p = 0.50$) |
| **5.10.3 Headache: sipuleucel-T** | | | | | |
| Higano et al. 2009 | 2 | 65 | 0 | 33 | 49.7% | 2.58 [0.13, 52.15] |
| Kantoff et al. 2010 | 1 | 338 | 0 | 168 | 50.3% | 1.50 [0.06, 36.52] |
| Small et al. 2006 | 0 | 82 | 0 | 45 | Not estimable |
| **Subtotal (95% CI)** | 485 | 246 | 246 | 100.0% | 2.03 [0.23, 17.90] |
| **Total events** | 3 | 0 | 3 | | |
| Heterogeneity: $\chi^2 = 0.06, df = 1$ ($p = 0.81$); $I^2 = 0$% |
| Test for overall effect: $Z = 0.64$ ($p = 0.52$) |
| **5.10.4 Headache: androgen receptor-directed therapies** | | | | | |
| Beer and Tombal 2014 | 2 | 871 | 3 | 844 | 82.0% | 0.65 [0.11, 3.86] |
| Scher et al. 2012 | 6 | 800 | 0 | 399 | 18.0% | 6.49 [0.37, 114.95] |
| **Subtotal (95% CI)** | 1671 | 1243 | 3 | 100.0% | 1.70 [0.44, 6.58] |
| **Total events** | 8 | 3 | 11 | | |
| Heterogeneity: $\chi^2 = 1.96, df = 1$ ($p = 0.16$); $I^2 = 49$% |
| Test for overall effect: $Z = 0.76$ ($p = 0.45$) |
| **5.10.5 Back pain: sipuleucel-T** | | | | | |
| Higano et al. 2009 | 2 | 65 | 1 | 33 | 10.5% | 1.02 [0.10, 10.79] |
| Kantoff et al. 2010 | 12 | 338 | 8 | 168 | 84.4% | 0.75 [0.31, 1.79] |
| Small et al. 2006 | 2 | 82 | 0 | 45 | 5.1% | 2.77 [0.14, 56.50] |
| **Subtotal (95% CI)** | 485 | 246 | 246 | 100.0% | 0.88 [0.40, 1.91] |
| **Total events** | 16 | 9 | 25 | | |
| Heterogeneity: $\chi^2 = 0.71, df = 2$ ($p = 0.70$); $I^2 = 0$% |
| Test for overall effect: $Z = 0.33$ ($p = 0.74$) |
| **5.10.6 Back pain: androgen receptor-directed therapies** | | | | | |
| Beer and Tombal 2014 | 22 | 871 | 25 | 844 | 32.2% | 0.85 [0.48, 1.50] |
| Fizazi et al. 2012 | 56 | 791 | 40 | 394 | 67.8% | 0.70 [0.47, 1.03] |
| **Subtotal (95% CI)** | 1662 | 1238 | 65 | 100.0% | 0.75 [0.54, 1.03] |
| **Total events** | 78 | 65 | 143 | | |
| Heterogeneity: $\chi^2 = 0.33, df = 1$ ($p = 0.56$); $I^2 = 0$% |
| Test for overall effect: $Z = 1.79$ ($p = 0.07$) |
| **5.10.7 Arthralgia: sipuleucel-T** | | | | | |
| Higano et al. 2009 | 2 | 65 | 0 | 33 | 8.3% | 2.58 [0.13, 52.15] |
| Kantoff et al. 2010 | 7 | 338 | 5 | 168 | 83.7% | 0.70 [0.22, 2.16] |
| Small et al. 2006 | 1 | 82 | 0 | 45 | 8.1% | 1.66 [0.07, 39.99] |
| **Subtotal (95% CI)** | 485 | 246 | 246 | 100.0% | 0.93 [0.35, 2.48] |
| **Total events** | 10 | 5 | 15 | | |
| Heterogeneity: $\chi^2 = 0.82, df = 2$ ($p = 0.66$); $I^2 = 0$% |
| Test for overall effect: $Z = 0.15$ ($p = 0.88$) |

**Figure 5:** Continued.
5.10.8 Arthralgia: androgen receptor-directed therapies

| Study            | Cases | Controls | Grade 3 | Grade 4 | Grade 5 | Subtotal (95% CI) |
|------------------|-------|----------|---------|---------|---------|------------------|
| Beer and Tombal 2014 | 12/871| 9/844    | 28.7%   |         |         | 1.29 [0.55, 3.05] |
| Fizazi et al. 2012 | 40/791| 17/394   | 71.3%   |         |         | 1.17 [0.67, 2.04] |
| **Subtotal**     | **52/1662** | **26/1238** | **100.0%** |       |         | **1.21 [0.76, 1.92]** |

Heterogeneity: \( \chi^2 = 0.03, df = 1 \) \((p = 0.85)\); \( I^2 = 0\% \)
Test for overall effect: \( Z = 0.79 \) \((p = 0.43)\)

5.10.9 Constipation: sipuleucel-T

| Study            | Cases | Controls | Grade 3 | Grade 4 | Grade 5 | Subtotal (95% CI) |
|------------------|-------|----------|---------|---------|---------|------------------|
| Kantoff et al. 2010 | 0/338| 2/168    | 72.1%   |         |         | 0.10 [0.00, 2.07] |
| Small et al. 2006  | 1/82 | 1/45     | 27.9%   |         |         | 0.55 [0.04, 8.57] |
| **Subtotal**     | **1/420** | **3/213** | **100.0%** |       |         | **0.23 [0.03, 1.48]** |

Heterogeneity: \( \chi^2 = 0.00, df = 1 \) \((p = 0.97)\); \( I^2 = 0\% \)
Test for overall effect: \( Z = 1.55 \) \((p = 0.12)\)

5.10.10 Constipation: androgen receptor-directed therapies

| Study            | Cases | Controls | Grade 3 | Grade 4 | Grade 5 | Subtotal (95% CI) |
|------------------|-------|----------|---------|---------|---------|------------------|
| Beer and Tombal 2014 | 4/871| 3/844    | 36.3%   |         |         | 1.29 [0.29, 5.76] |
| Fizazi et al. 2012 | 10/791| 4/394    | 63.7%   |         |         | 1.25 [0.39, 3.95] |
| **Subtotal**     | **14/1662** | **7/1238** | **100.0%** |       |         | **1.26 [0.51, 3.14]** |

Heterogeneity: \( \chi^2 = 0.68, df = 1 \) \((p = 0.41)\); \( I^2 = 0\% \)
Test for overall effect: \( Z = 1.55 \) \((p = 0.12)\)

5.10.11 Diarrhea: sipuleucel-T

| Study            | Cases | Controls | Grade 3 | Grade 4 | Grade 5 | Subtotal (95% CI) |
|------------------|-------|----------|---------|---------|---------|------------------|
| Kantoff et al. 2010 | 1/338| 3/168    | 100.0%  |         |         | 0.17 [0.02, 1.58] |
| **Subtotal**     | **1/338** | **3/168** | **100.0%** |       |         | **0.17 [0.02, 1.58]** |

Heterogeneity: not applicable
Test for overall effect: \( Z = 1.56 \) \((p = 0.12)\)

5.10.12 Diarrhea: androgen receptor-directed therapies

| Study            | Cases | Controls | Grade 3 | Grade 4 | Grade 5 | Subtotal (95% CI) |
|------------------|-------|----------|---------|---------|---------|------------------|
| Beer and Tombal 2014 | 2/871| 3/844    | 27.6%   |         |         | 0.65 [0.11, 3.86] |
| Fizazi et al. 2012 | 9/791| 5/394    | 60.4%   |         |         | 0.90 [0.30, 2.66] |
| Scher et al. 2012  | 9/800| 1/399    | 12.1%   |         |         | 4.49 [0.57, 35.31] |
| **Subtotal**     | **20/2462** | **9/1637** | **100.0%** |       |         | **1.26 [0.56, 2.83]** |

Heterogeneity: \( \chi^2 = 2.37, df = 2 \) \((p = 0.31\); \( I^2 = 16\% \)
Test for overall effect: \( Z = 0.56 \) \((p = 0.57)\)

3.7. Publication Bias. Funnel plot for publication bias was performed on study outcome of OS. Figure 6 shows symmetry funnel plot, indicating that there was no significant evidence of publication bias.

4. Discussion

Researches on novel treatments for CRPC have gained increasing interest in the past few years, especially those on sipuleucel-T and AR-directed therapies. This meta-analysis investigated the efficacy and safety of sipuleucel-T and AR-directed therapies, providing valuable information that might be useful clinical evidence on the treatments for CRPC. We found that both sipuleucel-T and AR-directed therapies could significantly improve OS in patients with CRPC, with favorable safety. AR-directed therapies appear to have superior effects in improving TTP and in reduction of PSA level. However, there are still debates over the efficacy and optimal regimen of these new treatment methods.

It has been known that traditional chemotherapeutic drugs lacked the selectivity on target tumor cells, which may cause different damage to normal cells, or even serious effects on patients. For example, Lim et al. indicated that adverse effects of docetaxel including edema, neurotoxicity, and hair loss limit its application [37]. Zhou et al. also showed 2.7% of CRPC patients died after docetaxel plus prednisone therapy,
Table 3: Analyses of adverse events (grade ≥ 3).

| Adverse events | References | Relative risk (95% confidence interval) | p       | Heterogeneity |
|----------------|------------|----------------------------------------|---------|---------------|
| Sipuleucel-T   |            |                                        |         |               |
| Fatigue        | Small et al., 2006 | 0.89 (0.27–3.01)              | 0.86    | p = 0.81, I² = 0% |
| Headache       | Higano et al., 2009 | 2.03 (0.23–1.79)              | 0.52    | p = 0.81, I² = 0% |
| Back pain      | Kantoff et al., 2010 | 0.88 (0.4–1.91)                | 0.74    | p = 0.7, I² = 0% |
| Arthralgia     |            | 0.93 (0.35–2.48)                | 0.88    | p = 0.66, I² = 0% |
| Constipation   |            | 0.23 (0.03–1.48)                | 0.12    | p = 0.41, I² = 0% |
| Diarrhea       |            | 0.17 (0.02–1.58)                | 0.12    |               |

Androgen receptor-directed therapies

| Adverse events | References | Relative risk (95% confidence interval) | p       | Heterogeneity |
|----------------|------------|----------------------------------------|---------|---------------|
| Fatigue        | Fizazi et al., 2012 | 0.92 (0.49–1.93)              | 0.5     | p = 0.84, I² = 0% |
| Headache       | Scher et al., 2012 | 1.7 (0.44–6.58)                | 0.45    | p = 0.16, I² = 49% |
| Back pain      | Beer and Tombal, 2014 | 0.75 (0.54–1.03)              | 0.07    | p = 0.56, I² = 0% |
| Arthralgia     | Rathkopf et al., 2014 | 1.21 (0.76–1.92)              | 0.43    | p = 0.85, I² = 0% |
| Constipation   |            | 1.26 (0.51–3.14)                | 0.62    | p = 0.97, I² = 0% |
| Diarrhea       |            | 1.26 (0.56–2.83)                | 0.57    | p = 0.31, I² = 16% |

58.56% had neutropenia, and 19.82% had leukopenia [38]. Unlike the traditional ones, sipuleucel-T and AR-directed therapies target tumor cells, thus causing little toxic effects on normal cells due to high selectivity. For instance, AA and Enz antagonize androgen receptors to inhibit the activity of tumor cells. Similarly, sipuleucel-T could elicit immune response targeting against antigen prostatic acid phosphatase (PAP) that is highly expressed in most prostate cancer cells [39, 40].

Many results showed that sipuleucel-T and AR-directed therapies improved the overall survival [29, 31–36] by exerting different effects on TTP, PSA level, and AEs. Although surgery, radiotherapy, or chemotherapy had stopped for a period of time before the new drugs clinical trials were given, it is still hard to rule out the possibility of the influence by the former treatments. Therefore, further clinical validation is needed. Beyond that, we paid more attention to the sequela, applicable scopes, and contraindications of these treatments.

All trials had strict selection of patients. To be an eligible case for sipuleucel-T trial, histological confirmation on castrate-resistant prostate cancer, serum testosterone level <50 ng/dL, and a considerable somatic function for expected survival were required. Patients accepted for AA trial should have no more than two previous chemotherapies, at least one previous docetaxel therapy, and mild symptoms or no symptoms (radiographic progression in soft tissue or bone with or without PSA progression, PSA <50 ng/dL, and ECOG performance status of 2 or less). And Enz had similar requirement to AA’s.

Upon the drug usage, patients from sipuleucel-T trials were scheduled to undergo leukapheresis procedures every 2 week for a total of three times, and on the second day after each leukapheresis procedure, patients were treated by infusion of sipuleucel-T or placebo. Patients from AA trials received abiraterone acetate 1000 mg once daily plus prednisone 5 mg twice daily by oral or placebo plus prednisone. And in Enz trials patients received enzalutamide 160 mg orally once daily or matched placebo.

We found that in AA trials patients with lower score of ECOG, age ≥ 65 years, and PSA level > or < median had the higher HR. On the contrary, in enzalutamide trials, patients with age ≥ 65 years, higher score of ECOG, and PSA Level > median had the higher HR. While in sipuleucel-T trials, patients with age < median, PSA < or > median, and higher score of ECOG had the higher HR. Such differences may be related to the characteristics of different individuals. Drake 2012 indicated that the subgroup of patients aged less than 65 years did not favor sipuleucel-T. Another observation by them was the potential harm from the IMPACT study interventions, because, to some extent, sipuleucel-T broke the immune balance [41].
Challenges remain in finding the optimal regimen for sipuleucel-T and AR-directed therapies. Combined sipuleucel-T, AA, and prednisone formula has been proposed as a novel treatment diagram in CRPC. Research has shown that concurrent administration of AA and prednisone did not blunt immunologic effects or alter immune parameters that correlate with sipuleucel-T’s clinical benefits [42]. Cumulative APC activation, cumulative APC number, total nucleated cell counts, and immune responses to sipuleucel-T were not affected by coadministration of AA and prednisone. Such combination of treatments was well tolerated, with no new risk marker emerging. Sipuleucel-T is recommended as the first-line treatment for patients with CRPC by the National Comprehensive Cancer Network [43] and it is recommended as early use in asymptomatic CRPC or patients with mild symptoms. Comparatively, treatments with AA and Enz could induce symptomatic disease progression. Badrising et al. 2014 reported that tolerance could be built up when combining Enz and AA [44]. This was possibly a result of mutation of AR induced by prednisone, which will subsequently impact the effect of Enz on AR. Therefore, it appears that there is limited clinical benefit for combination or sequential use of Enz and AA [45–48].

Competing Interests

The authors declared no competing interests.

Authors’ Contributions

Renliang Yi, Baoxin Chen, and Zhiheng Zhou conceived and designed the research. Renliang Yi, Baoxin Chen, Peng Duan, and Chen Yuan carried out literature search. Chanjiao Zheng and Huanyu Shen carried out data extraction. Qun Liu and Weilin Ou carried out quality assessment. Baoxin Zheng and Huanyu Shen carried out manuscript preparation. Chanjiao Zheng, Huanyu Shen, and Zhiheng Zhou carried out manuscript revision. Renliang Yi and Baoxin Chen contributed equally to this work.

Acknowledgments

The authors thank Dr. Zining Lei for her helpful suggestions and advice on this paper. This work was supported by The Healthcare Project of the Health Department of the General Logistics Department of the Chinese People’s Liberation Army (Renliang Yi: 14BJZ34), the National Natural Science Foundation of China (Zhiheng Zhou: 81473001), and the Training Project of Outstanding Young College Teachers in Guangdong Province, China (Zhiheng Zhou: Yq2013J38).

References

[1] World Health Organization, Programmes and projects: Cancer, http://www.who.int/cancer/en/.
[2] J. Ferlay, E. Steliarova-Foucher, J. Lortet-Tieulent et al., “Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012,” European Journal of Cancer, vol. 49, no. 6, pp. 1374–1403, 2013.
[3] R. L. Siegel, K. D. Miller, and A. Jemal, “Cancer statistics, 2015,” CA: A Cancer Journal for Clinicians, vol. 65, no. 1, pp. 5–29, 2015.
[4] G. L. Plosker, “Sipuleucel-T: in metastatic castration-resistant prostate cancer,” Drugs, vol. 71, no. 1, pp. 101–108, 2011.
[5] Ö. Acar, T. Eser, and N. A. Lack, “New therapeutics to treat castrate-resistant prostate cancer,” The Scientific World Journal, vol. 2013, Article ID 379641, 8 pages, 2013.
[6] S. M. Geary, C. D. Lemke, D. M. Lubarooff, and A. K. Salem, “Proposed mechanisms of action for prostate cancer vaccines,” Nature Reviews Urology, vol. 10, no. 3, pp. 149–160, 2013.
[7] C. R. Pound, A. W. Partin, M. A. Eisenberger, D. W. Chan, J. D. Pearson, and P. C. Walsh, “Natural history of progression after PSA elevation following radical prostatectomy,” Journal of the American Medical Association, vol. 281, no. 17, pp. 1591–1597, 1999.
[8] D. L. Suzman and E. S. Antonarakis, “Castration-resistant prostate cancer: latest evidence and therapeutic implications,” Therapeutic Advances in Medical Oncology, vol. 6, no. 4, pp. 167–179, 2014.
[9] R. Petrioli, E. Francini, and G. Roviello, “Is there still a place for docetaxel rechallenge in prostate cancer?” World Journal of Clinical Oncology, vol. 6, no. 5, pp. 99–103, 2015.
[10] S. Badrising, V. van der Noort, I. M. van Oort et al., “Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment,” Cancer, vol. 120, no. 7, pp. 968–975, 2014.
[11] C.-H. Ohlmann, “Chemotherapy of prostate cancer,” Urologie, vol. 54, no. 10, pp. 1461–1470, 2015.
[12] C. Printz, “New prostate cancer drugs hold promise,” Cancer, vol. 119, no. 2, pp. 247–248, 2013.
[13] D. Lorente, J. Mateo, R. Perez-Lopez, J. S. de Bono, and G. Attard, “Sequencing of agents in castration-resistant prostate cancer,” The Lancet Oncology, vol. 16, no. 6, pp. e279–e292, 2015.
[14] R. M. Bambury and D. E. Rathkopf, “Novel and next-generation androgen receptor-directed therapies for prostate cancer: beyond abiraterone and enzalutamide,” Urologic Oncology: Seminars and Original Investigations, vol. 34, no. 8, pp. 348–355, 2016.
[15] L. T. Dauer, M. J. Williamson, J. Humm et al., “Radiation safety considerations for the use of 223RaCl2 de in men with castration-resistant prostate cancer,” Health Physics, vol. 106, no. 4, pp. 494–504, 2014.
[16] R. Iacovelli, A. Palazzo, G. Procopio, P. Gazzaniga, and E. Cortesi, “Abiraterone acetate in castration-resistant prostate cancer,” Anti-Cancer Drugs, vol. 23, no. 3, pp. 247–254, 2012.
[17] S. Bhattacharyya, M. Hirmand, D. Phung, and S. van Os, “Development of enzalutamide for metastatic castration-resistant prostate cancer,” Annals of the New York Academy of Sciences, vol. 1358, no. 1, pp. 13–27, 2015.
[18] S. Lebdai, V. Basset, J. Branchereau et al., “What do we know about treatment sequencing of abiraterone, enzalutamide, and chemotherapy in metastatic castration-resistant prostate cancer?” World Journal of Urology, vol. 34, no. 5, pp. 617–624, 2016.
castration-resistant prostate cancer," Journal of Clinical Oncology, vol. 28, no. 7, pp. 1099–1105, 2010.

[21] P. G. Kluetz, Y.-M. Ning, V. E. Maher et al., "Abiraterone acetate in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer: U.S. food and drug administration drug approval summary," Clinical Cancer Research, vol. 19, no. 24, pp. 6650–6656, 2013.

[22] Y. M. Ning, W. Pierce, V. E. Maher et al., "Enzalutamide for treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel: U.S. food and drug administration drug approval summary," Clinical Cancer Research, vol. 19, no. 22, pp. 6067–6073, 2013.

[23] M. A. Cheever and C. S. Higano, "PROVENGE (sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine," Clinical Cancer Research, vol. 17, no. 11, pp. 3520–3526, 2011.

[24] W. Kim and C. J. Ryan, "Quo vadis: advanced prostate cancer-clinical care and clinical research in the era of multiple androgen receptor-directed therapies," Cancer, vol. 121, no. 3, pp. 361–371, 2015.

[25] B. A. Gartrell and F. Saad, "Abiraterone in the management of castration-resistant prostate cancer prior to chemotherapy," Therapeutic Advances in Urology, vol. 7, no. 4, pp. 194–202, 2015.

[26] J. B. Aragon-Ching, "Further analysis of PREVAIL: enzalutamide use in chemotherapy-naïve men with metastatic castration-resistant prostate cancer," Asian Journal of Andrology, vol. 16, no. 6, pp. 803–804, 2014.

[27] P. A. Burch, J. K. Breen, J. C. Buckner et al., "Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer," Clinical Cancer Research, vol. 6, no. 6, pp. 2175–2182, 2000.

[28] C. J. Paller and E. S. Antonarakis, "Sipuleucel-T for the treatment of metastatic prostate cancer: promise and challenges," Human Vaccines & Immunotherapeutics, vol. 8, no. 4, pp. 509–519, 2012.

[29] E. J. Small, P. F. Schellhammer, C. S. Higano et al., "Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer," Journal of Clinical Oncology, vol. 24, no. 19, pp. 3089–3094, 2006.

[30] G. A. Wells, B. Shea, D. O’Connell et al., "The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses," http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm.

[31] C. S. Higano, P. F. Schellhammer, E. J. Small et al., "Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer," Cancer, vol. 115, no. 16, pp. 3670–3679, 2009.

[32] P. W. Kantoff, C. S. Higano, N. D. Shore et al., "Sipuleucel-T immunotherapy for castration-resistant prostate cancer," The New England Journal of Medicine, vol. 363, no. 5, pp. 411–422, 2010.

[33] K. Fizazi, H. I. Scher, A. Molina et al., "Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study," The Lancet Oncology, vol. 13, no. 10, pp. 983–992, 2012.

[34] D. E. Rathkopf, M. R. Smith, J. S. DeBono et al., "Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302)," European Urology, vol. 66, no. 5, pp. 815–825, 2014.

[35] H. I. Scher, K. Fizazi, F. Saad et al., "Increased survival with enzalutamide in prostate cancer after chemotherapy," The New England Journal of Medicine, vol. 367, no. 13, pp. 1187–1197, 2012.

[36] T. M. Beer and B. Tombal, "Enzalutamide in metastatic prostate cancer before chemotherapy," The New England Journal of Medicine, vol. 371, no. 18, pp. 1755–1756, 2014.

[37] H. Lim, K. M. Kim, S. Jeong, E. K. Choi, and J. Jung, "Chrysins increases the therapeutic efficacy of docetaxel and mitigates docetaxel-induced edema," Integrative Cancer Therapies, 2016.

[38] T. Zhou, S.-X. Zeng, D.-W. Ye et al., "A multicenter, randomized clinical trial comparing the three-weekly docetaxel regimen plus prednisone versus mitoxantone plus prednisone for Chinese patients with metastatic castration refractory prostate cancer," PLoS ONE, vol. 10, no. 1, Article ID e0117002, 2015.

[39] N. Agarwal, G. Di Lorenzo, G. Sonpavde, and J. Bellmunt, "New agents for prostate cancer," Annals of Oncology, vol. 25, no. 9, Article ID mdu038, pp. 1700–1709, 2014.

[40] E. Anassi and U. A. Ndefo, "Sipuleucel-T (Provenge) injection the first immunotherapy agent (Vaccine) for hormone-refractory prostate cancer," P and T, vol. 36, no. 4, pp. 197–202, 2011.

[41] C. G. Drake, "Re: interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer," Journal of the National Cancer Institute, vol. 104, no. 18, p. 1422, 2012.

[42] E. J. Small, R. S. Lance, T. A. Gardner et al., "A randomized phase II trial of sipuleucel-T with concurrent versus sequential abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer," Clinical Cancer Research, vol. 21, no. 17, pp. 3862–3869, 2015.

[43] J. Mohler, A. Armstrong, R. Bahnson et al., NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer, V.4, 2013, https://www.nccn.org/.

[44] S. Badrising, V. Van Der Noort, I. M. Van Oort et al., "Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment," Cancer, vol. 120, no. 7, pp. 968–975, 2014.

[45] Y. Loriot, D. Bianchini, E. Ileana et al., "Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100)," Annals of Oncology, vol. 24, no. 7, pp. 1807–1812, 2013.

[46] K. L. Noonan, S. North, R. L. Biting, A. J. Armstrong, S. L. Ellard, and K. N. Chi, "Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide," Annals of Oncology, vol. 24, no. 7, pp. 1802–1807, 2013.

[47] A. A. Azad, B. J. Eigl, R. N. Murray, C. Kollmannsberger, and K. N. Chi, "Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naïve metastatic castration-resistant prostate cancer patients," European Urology, vol. 67, no. 1, pp. 23–29, 2015.

[48] A. J. Schrader, M. Boegemann, C.-H. Ohlmann et al., "Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone," European Urology, vol. 65, no. 1, pp. 30–36, 2014.